Dr Natália Sampaio is a member of the Regulation of Interferon and Innate Signalling Research group in the Centre for Innate Immunity and Infectious Diseases.

Learn more about my group's research

Dr Natalia Sampaio chosen for the 2021 Hudson Institute Emerging Leaders program.

Areas of interest

COVID-19 Endometriosis Inflammation and cancer Inflammatory bowel disease (IBD) Influenza Lung cancer Microbiome in health and disease Ovarian cancer

Research group

Regulation of Interferon and Innate Signalling


Dr Natália Sampaio is a postdoctoral researcher working on RNA sensing in the innate immune system. She applies cutting-edge methods to understand how cytosolic RNA receptors, such as MDA5 and PKR, are activated and regulated. She is particularly interested in their role in both viral infection and inflammatory diseases. Dr Sampaio is also investigating how these RNA receptors may respond to novel mRNA therapies, such as the COVID-19 mRNA vaccines.

Dr Sampaio obtained her PhD at the Walter and Eliza Hall Institute in 2016, where she studied innate immune responses and host-pathogen interactions of the malaria parasite Plasmodium falciparum. Following this, she joined the group of Professor Jan Rehwinkel at the University of Oxford, where she investigated cytosolic nucleic acid receptors in the context of viral infection and interferonopathies. In 2021, she returned to Melbourne to join the research group of Professor Paul Hertzog at Hudson Institute, where she established novel lines of investigation on RNA sensing. In 2021, Dr Sampaio was selected as Hudson Institute Emerging Leader. Her work has been supported by both government grants and industry collaborations.